BANKINTER SECURITIES, S.V.,S.A.
IMPULSA CAPITAL S.L.
CL/ COSO 55, 50001 ZARAGOZA
|2016||2017||2018 until 16/01|
Period Close Price
Period Last Price
Period High Price
Period Low Price
Founded in Barcelona in 2006, Pangaea Oncology is a medical services company focused on precision oncology, personalized medicine based on genetic analyses to improve survival and quality of life for cancer patients.
The company has two main areas of activity: (i) its clinical care division, the Dr. Rosell Oncology Institute (IOR). Based on the concept of personalized medicine, IOR delivers medical oncology services and related activities at four of the largest hospitals of the Quirónsalud Group in Catalonia; (ii) its Diagnostic and R & D services division, providing diagnostic and in-vitro services to IOR patients and Pangaea's portfolio of pharmaceutical clients, including over 15 multinationals. Pangaea is highly invested in technology, focusing on the development of innovative, proprietary diagnostic techniques (its main commercialized asset is Liquid Biopsy), and development of targeted drugs - to early clinical trial stages - through a strategic agreement with Cancer Research Technology, UK.
The synergy between these areas forms the foundation of Pangaea's future growth strategy.
The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at email@example.com.
What is MaB
Financing for companies
MaB for investors
News and Publications
If an issue occurs, the message "TRADING" will change to "MARKET ISSUE" to reflect that a market event has occurred. By clicking on the Issue of the published alert it will be possible to access the information and intraday updates associated with this incident, which will be published immediately.
Note: BME will use its discretion to assign the severity of an incident